WO2007053796A3 - Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion - Google Patents

Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion Download PDF

Info

Publication number
WO2007053796A3
WO2007053796A3 PCT/US2006/060006 US2006060006W WO2007053796A3 WO 2007053796 A3 WO2007053796 A3 WO 2007053796A3 US 2006060006 W US2006060006 W US 2006060006W WO 2007053796 A3 WO2007053796 A3 WO 2007053796A3
Authority
WO
WIPO (PCT)
Prior art keywords
disorder
escitalopram
bupropion
nervous system
central nervous
Prior art date
Application number
PCT/US2006/060006
Other languages
French (fr)
Other versions
WO2007053796A2 (en
Inventor
Jeffrey Jonas
Anjana Bose
Joyce Tsai
Original Assignee
Forest Laboratories
Jeffrey Jonas
Anjana Bose
Joyce Tsai
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Forest Laboratories, Jeffrey Jonas, Anjana Bose, Joyce Tsai filed Critical Forest Laboratories
Priority to EP06846096A priority Critical patent/EP1954257A4/en
Priority to EA200801081A priority patent/EA200801081A1/en
Priority to AU2006308635A priority patent/AU2006308635A1/en
Priority to JP2008535806A priority patent/JP2009511606A/en
Priority to BRPI0617382A priority patent/BRPI0617382A2/en
Priority to CA002625835A priority patent/CA2625835A1/en
Publication of WO2007053796A2 publication Critical patent/WO2007053796A2/en
Publication of WO2007053796A3 publication Critical patent/WO2007053796A3/en
Priority to IL190831A priority patent/IL190831A0/en
Priority to NO20082203A priority patent/NO20082203L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

The present invention relates to a method of treating a central nervous system disorder, such as a mood disorder (e.g., major depressive disorder) or an anxiety disorder (e.g., general anxiety disorder, social anxiety disorder, post traumatic stress disorder, and panic disorder) with a low dose combination of escitalopram and bupropion.
PCT/US2006/060006 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion WO2007053796A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP06846096A EP1954257A4 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
EA200801081A EA200801081A1 (en) 2005-10-14 2006-10-16 METHODS OF TREATING DISORDERS OF THE CENTRAL NERVOUS SYSTEM BY COMBINATION OF SMALL DOSES OF ESCITALOPRAM AND BUPROPION
AU2006308635A AU2006308635A1 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
JP2008535806A JP2009511606A (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders using a low-dose combination of escitalopram and bupropion
BRPI0617382A BRPI0617382A2 (en) 2005-10-14 2006-10-16 METHODS FOR TREATMENT OF A DISORDER OF THE CENTRAL NERVOUS SYSTEM IN A PATIENT, FOR TREATMENT FOR A PATIENT SUFFERING FROM CONDITIONS AND A SEXUAL DYSFUNCTION, AND FOR REDUCING A DELAY IN THERAPEUTIC EFFECTIVENESS FOLLOWING INITIATION OF TREATMENT
CA002625835A CA2625835A1 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
IL190831A IL190831A0 (en) 2005-10-14 2008-04-13 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
NO20082203A NO20082203L (en) 2005-10-14 2008-05-14 Methods for treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US72727605P 2005-10-14 2005-10-14
US60/727,276 2005-10-14
US81088206P 2006-06-02 2006-06-02
US60/810,882 2006-06-02
US80408606P 2006-06-06 2006-06-06
US60/804,086 2006-06-06

Publications (2)

Publication Number Publication Date
WO2007053796A2 WO2007053796A2 (en) 2007-05-10
WO2007053796A3 true WO2007053796A3 (en) 2007-11-29

Family

ID=38006532

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2006/060006 WO2007053796A2 (en) 2005-10-14 2006-10-16 Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion

Country Status (11)

Country Link
US (2) US7569605B2 (en)
EP (1) EP1954257A4 (en)
JP (1) JP2009511606A (en)
KR (1) KR20080080094A (en)
AU (1) AU2006308635A1 (en)
BR (1) BRPI0617382A2 (en)
CA (1) CA2625835A1 (en)
EA (1) EA200801081A1 (en)
IL (1) IL190831A0 (en)
NO (1) NO20082203L (en)
WO (1) WO2007053796A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932628B2 (en) 2005-06-27 2015-01-13 Valeant International Bermuda Modified release formulations of a bupropion salt

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7671094B2 (en) 2005-06-27 2010-03-02 Biovail Laboratories International S.R.L. Bupropion hydrobromide and therapeutic applications
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
WO2009035473A2 (en) * 2007-09-13 2009-03-19 Sanfilippo Louis C Method of treating binge eating disorder, obesity resulting from binge eating behavior and depressive disorders
US20090246276A1 (en) * 2008-01-28 2009-10-01 Graham Jackson Pharmaceutical Compositions
BRPI1012038A2 (en) * 2009-05-26 2017-06-27 Shire Llc methods of enhancing the effects of selective serotonin reuptake inhibitors in mammals
WO2012028834A1 (en) * 2010-09-01 2012-03-08 Marcel Petrus Maria Bartels Use of bupropion in treating sexual dysfunction
WO2014186410A1 (en) 2013-05-13 2014-11-20 NeuOra Microceuticals, LLC Long lasting breath mint
IL304080A (en) * 2021-01-28 2023-08-01 Sage Therapeutics Inc Use of neuroactive steroids for treatment of sexual dysfunction

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052340A1 (en) * 1999-03-01 2002-05-02 Jerussi Thomas P. Bupropion metabolites and methods of their synthesis and use
US20040198809A1 (en) * 2001-05-01 2004-10-07 Connie Sanchez Use of enantiomeric pure escitalopram

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759838A (en) 1969-12-04 1971-06-03 Wellcome Found KETONES WITH BIOLOGICAL ACTIVITY
US3885046A (en) 1969-12-04 1975-05-20 Burroughs Wellcome Co Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression
USRE33994E (en) 1983-08-16 1992-07-14 Burroughs Wellcome Co. Pharmaceutical delivery system
US4507323A (en) * 1984-07-25 1985-03-26 Burroughs Wellcome Co. Treatment of psychosexual dysfunctions
US4723958A (en) 1986-05-23 1988-02-09 Merck & Co., Inc. Pulsatile drug delivery system
GB8814057D0 (en) 1988-06-14 1988-07-20 Lundbeck & Co As H New enantiomers & their isolation
US5007790A (en) 1989-04-11 1991-04-16 Depomed Systems, Inc. Sustained-release oral drug dosage form
US5582837A (en) 1992-03-25 1996-12-10 Depomed, Inc. Alkyl-substituted cellulose-based sustained-release oral drug dosage forms
US5260068A (en) 1992-05-04 1993-11-09 Anda Sr Pharmaceuticals Inc. Multiparticulate pulsatile drug delivery system
GB9217295D0 (en) 1992-08-14 1992-09-30 Wellcome Found Controlled released tablets
US5260069A (en) 1992-11-27 1993-11-09 Anda Sr Pharmaceuticals Inc. Pulsatile particles drug delivery system
US5541231A (en) 1993-07-30 1996-07-30 Glaxo Wellcome Inc. Stabilized Pharmaceutical
GB9315856D0 (en) 1993-07-30 1993-09-15 Wellcome Found Stabilized pharmaceutical
US5358970A (en) 1993-08-12 1994-10-25 Burroughs Wellcome Co. Pharmaceutical composition containing bupropion hydrochloride and a stabilizer
MY113429A (en) 1995-02-28 2002-02-28 Univ Temple Controlled release tablet containing swellable polyethylene oxide
US5656294A (en) 1995-06-07 1997-08-12 Cibus Pharmaceutical, Inc. Colonic delivery of drugs
US5972389A (en) 1996-09-19 1999-10-26 Depomed, Inc. Gastric-retentive, oral drug dosage forms for the controlled-release of sparingly soluble drugs and insoluble matter
US5840329A (en) 1997-05-15 1998-11-24 Bioadvances Llc Pulsatile drug delivery system
ES2248908T7 (en) 1997-06-06 2014-11-24 Depomed, Inc. Dosage forms of drugs orally and gastric retention for continued release of highly soluble drugs
US6110973A (en) * 1998-01-29 2000-08-29 Sepracor Methods for treating obesity and weight gain using optically pure (-)-bupropion
US6372254B1 (en) 1998-04-02 2002-04-16 Impax Pharmaceuticals Inc. Press coated, pulsatile drug delivery system suitable for oral administration
US6096341A (en) 1998-10-30 2000-08-01 Pharma Pass Llc Delayed release tablet of bupropion hydrochloride
NZ511442A (en) 1998-11-02 2003-02-28 Elan Corp Plc Multiparticulate modified release composition for multiple dosing of ADD patients with methylphenidate HCl
US8545880B2 (en) 1999-02-26 2013-10-01 Andrx Pharmaceuticals, Llc Controlled release oral dosage form
AU4334700A (en) 1999-04-06 2000-10-23 Shubha Chungi Pharmaceutical dosage form for pulsatile delivery of methylphenidate
AR021155A1 (en) 1999-07-08 2002-06-12 Lundbeck & Co As H TREATMENT OF NEUROTIC DISORDERS
EP1220658A1 (en) 1999-09-28 2002-07-10 H. Lundbeck A/S Melt granulated composition and modified release dosage form prepared from said composition
DE69935355T2 (en) 1999-10-25 2007-11-08 H. Lundbeck A/S, Valby Process for the preparation of citalopram
US6627223B2 (en) 2000-02-11 2003-09-30 Eurand Pharmaceuticals Ltd. Timed pulsatile drug delivery systems
DK1325008T3 (en) * 2000-07-31 2006-02-13 Hoffmann La Roche piperazine
US6500457B1 (en) 2000-08-14 2002-12-31 Peirce Management, Llc Oral pharmaceutical dosage forms for pulsatile delivery of an antiarrhythmic agent
AR034612A1 (en) 2001-06-25 2004-03-03 Lundbeck & Co As H PROCESS FOR THE PREPARATION OF RACEMIC CITALOPRAM AND / OR OF THE S- OR R-CITALOPRAM THROUGH THE SEPARATION OF A MIXING OF R- AND S-CITALOPRAM
AR034759A1 (en) 2001-07-13 2004-03-17 Lundbeck & Co As H METHOD FOR THE PREPARATION OF ESCITALOPRAM
PL366995A1 (en) 2001-07-31 2005-02-07 H.Lundbeck A/S Crystalline composition containing escitalopram
US20030124196A1 (en) 2001-08-22 2003-07-03 Susan Weinbach Pulsatile release compositions and methods for enhanced intestinal drug absorption
US7163696B2 (en) 2001-10-11 2007-01-16 Pfizer Inc. Pharmaceutical formulations
IS7239A (en) 2001-12-14 2004-04-29 H. Lundbeck A/S Process for the production of acitalopram
CA2483827C (en) 2002-04-29 2012-01-24 Amir H. Shojaei Pharmaceutical formulations with improved bioavailability
CA2511142A1 (en) 2002-12-23 2004-07-08 H. Lundbeck A/S Escitalopram hydrobromide and a method for the preparation thereof
CA2530038C (en) 2002-12-24 2012-10-02 Immunofrontier, Inc. Vaccines comprising polynucleotides
US7687645B2 (en) 2003-03-21 2010-03-30 H. Lundbeck A/S Intermediates for the preparation of citalopram and escitalopram
US20050054688A1 (en) * 2003-08-08 2005-03-10 Pfizer Inc Selective serotonin reuptake inhibitors in the treatment of disease
US20050196453A1 (en) 2004-03-05 2005-09-08 H. Lundbeck A/S Crystalline composition containing escitalopram
RU2007103313A (en) * 2004-08-03 2008-09-10 ОРЕКСИДЖЕН ТЕРАПЬЮТИКС, ИНК. (Канада/США) (US) COMBINATION OF BUPROPINE AND OTHER COMPOSITION FOR EFFECTIVE WEIGHT LOSS

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020052340A1 (en) * 1999-03-01 2002-05-02 Jerussi Thomas P. Bupropion metabolites and methods of their synthesis and use
US20040198809A1 (en) * 2001-05-01 2004-10-07 Connie Sanchez Use of enantiomeric pure escitalopram

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
PHILLIPS ET AL.: "Depression and sexual desire", AMERICAN FAMILY PHYSICIAN, August 2000 (2000-08-01), XP008130580, Retrieved from the Internet <URL:http://www.affp.org/afp/20000815/782.html> *
RAMPELLO ET AL.: "Dopamine and Depression:Therapeutic Implications CNS", DRUGS, vol. 13, no. 1, January 2000 (2000-01-01), pages 35 - 45, XP008131431 *
TRINDADE ET AL.: "Adverse effects associated with selective serotonin reuptake inhibitors and trycyclic antidepressants: a meta-analysis", CANADIAN MEDICAL ASSOCIATION JOURNAL, vol. 159, no. 10, November 1998 (1998-11-01), pages 1245 - 1252, XP008129236 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8932628B2 (en) 2005-06-27 2015-01-13 Valeant International Bermuda Modified release formulations of a bupropion salt

Also Published As

Publication number Publication date
US20090264522A1 (en) 2009-10-22
CA2625835A1 (en) 2007-05-10
US20070203231A1 (en) 2007-08-30
EA200801081A1 (en) 2008-10-30
EP1954257A2 (en) 2008-08-13
IL190831A0 (en) 2008-12-29
US7569605B2 (en) 2009-08-04
KR20080080094A (en) 2008-09-02
EP1954257A4 (en) 2009-05-20
WO2007053796A2 (en) 2007-05-10
BRPI0617382A2 (en) 2017-07-11
NO20082203L (en) 2008-07-09
JP2009511606A (en) 2009-03-19
AU2006308635A1 (en) 2007-05-10

Similar Documents

Publication Publication Date Title
WO2007053796A3 (en) Methods of treating central nervous system disorders with a low dose combination of escitalopram and bupropion
NO20055907L (en) Method of treating an anxiety disorder
EP1863562A4 (en) Method of treating depression, mood disorders and anxiety disorders using neuromodulation
NO20084004L (en) Mono Column FPSO
WO2008067121A3 (en) Methods of treating cognitive impairment and dementia
TW200738270A (en) Method of treating depression using a TNFα antibody
EP2243760A3 (en) Oxidation inhibition of carbon-carbon composites
WO2007109097A3 (en) RNAi MODULATION OF TGF-BETA AND THERAPEUTIC USES THEREOF
WO2006009836A3 (en) Tdf-related compounds and analogs thereof
MX2007002470A (en) Substituted phenylaminothiazoles and use thereof.
WO2006037623A3 (en) New nuclear transcription factors regulators
WO2009061924A3 (en) Aldh-2 inhibitors in the treatment of psychiatric disorders
ATE447593T1 (en) LOW VISCOSE POLYADDITION COMPOUNDS CONTAINING URETDIONE GROUPS, METHOD FOR PRODUCTION AND USE
WO2006080549A3 (en) Method and composition for treating central nervous system disorders
WO2007047447A3 (en) Diuretic-like compound analogs useful for regulation of central nervous system disorders
WO2008042716A3 (en) Knowledge based encoding of data with multiplexing to facilitate compression
DE602005013895D1 (en) Device for the production of tire components.
ATE446299T1 (en) METHOD FOR PRODUCING 7-ETHYL-10-HYDROXYCAMPTOTHECINE
WO2012074561A3 (en) Methods and compositions for the treatment of anxiety disorders, including post traumatic stress disorder (ptsd) and related central nervous system (cns) disorders
WO2009115252A3 (en) Substituted pyrazolamides and the use thereof
WO2007070840A8 (en) Modified and pulsatile release pharmaceutical formulations of escitalopram
WO2007035872A3 (en) Tdf-related compounds and analogs thereof
WO2009137795A3 (en) Methods for treating endoplasmic reticulum (er) stress disorders
DK2108366T3 (en) Idebenone for the treatment of respiratory disease in muscular dystrophy
WO2007048080A3 (en) Stable pharmaceutical formulations containing escitalopram and bupropion

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200680046557.2

Country of ref document: CN

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 190831

Country of ref document: IL

ENP Entry into the national phase

Ref document number: 2008535806

Country of ref document: JP

Kind code of ref document: A

Ref document number: 2625835

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: MX/a/2008/004863

Country of ref document: MX

Ref document number: 2008040609

Country of ref document: EG

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2006308635

Country of ref document: AU

Ref document number: 2006846096

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12008501117

Country of ref document: PH

WWE Wipo information: entry into national phase

Ref document number: 568231

Country of ref document: NZ

Ref document number: 2370/CHENP/2008

Country of ref document: IN

Ref document number: 200801081

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 08049008

Country of ref document: CO

Ref document number: 1020087011544

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2006308635

Country of ref document: AU

Date of ref document: 20061016

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: PI0617382

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080414